Dr Reddy’s, Takeda Partner for Qdenga Dengue Vaccine

: Dr. Reddy’s Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market across India. Under the partnership, Dr. Reddy’s will be responsible for the distribution and marketing of Qdenga in India’s private healthcare market. The collaboration expands Dr. Reddy’s presence in the vaccines segment and adds a differentiated product to its domestic portfolio. Qdenga’s availability through a large pharmaceutical distribution network could improve access to dengue vaccination across India, while giving Dr. Reddy’s an opportunity to build a new revenue stream in the growing preventive healthcare market. The agreement also strengthens the company’s relationship with Takeda and broadens its portfolio beyond conventional pharmaceutical products. Commercial contribution will depend on vaccine adoption, pricing and private-market demand, but the partnership is strategically positive for Dr. Reddy’s. Stock Commentary – Dr. Reddy’s Laboratories DRREDDY – POSITIVE (7/10): The exclusive Qdenga distribution and marketing partnership strengthens Dr. Reddy’s presence in India’s vaccines and preventive healthcare segment. The agreement provides an opportunity to build a new domestic revenue stream while expanding its relationship with Takeda.